Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Glymphatic fluid transport controls paravascular clearance of AAV vectors from the brain
Giridhar Murlidharan, Andrew Crowther, Rebecca A. Reardon, Juan Song, Aravind Asokan
Giridhar Murlidharan, Andrew Crowther, Rebecca A. Reardon, Juan Song, Aravind Asokan
View: Text | PDF
Research Article Neuroscience Virology

Glymphatic fluid transport controls paravascular clearance of AAV vectors from the brain

  • Text
  • PDF
Abstract

Adeno-associated viruses (AAV) are currently being evaluated in clinical trials for gene therapy of CNS disorders. However, host factors that influence the spread, clearance, and transduction efficiency of AAV vectors in the brain are not well understood. Recent studies have demonstrated that fluid flow mediated by aquaporin-4 (AQP4) channels located on astroglial end feet is essential for exchange of solutes between interstitial and cerebrospinal fluid. This phenomenon, which is essential for interstitial clearance of solutes from the CNS, has been termed glial-associated lymphatic transport or glymphatic transport. In the current study, we demonstrate that glymphatic transport profoundly affects various aspects of AAV gene transfer in the CNS. Altered localization of AQP4 in aged mouse brains correlated with significantly increased retention of AAV vectors in the parenchyma and reduced systemic leakage following ventricular administration. We observed a similar increase in AAV retention and transgene expression upon i.c.v. administration in AQP4–/– mice. Consistent with this observation, fluorophore-labeled AAV vectors showed markedly reduced flux from the ventricles of AQP4–/– mice compared with WT mice. These results were further corroborated by reduced AAV clearance from the AQP4-null brain, as demonstrated by reduced transgene expression and vector genome accumulation in systemic organs. We postulate that deregulation of glymphatic transport in aged and diseased brains could markedly affect the parenchymal spread, clearance, and gene transfer efficiency of AAV vectors. Assessment of biomarkers that report the kinetics of CSF flux in prospective gene therapy patients might inform variable treatment outcomes and guide future clinical trial design.

Authors

Giridhar Murlidharan, Andrew Crowther, Rebecca A. Reardon, Juan Song, Aravind Asokan

×

Figure 6

Transduction and biodistribution of AAV vectors in systemic organs following intra-CSF administration in WT and AQP4–/– mice.

Options: View larger image (or click on image) Download as PowerPoint
Transduction and biodistribution of AAV vectors in systemic organs follo...
P0 WT or AQP4–/– mice were injected with equal viral titers (3.5 × 109 vg per animal) of AAV9 packaging the luciferase or the self-complementary GFP transgene driven by chicken β actin (CBA) or the hybrid chicken β actin promoter (CBh), respectively, into the left lateral ventricle. (A) For biodistribution studies, mice were sacrificed 3 days after AAV9-CBA-Luc administration. Vector genome (vg) copy numbers within the hearts and livers of WT and AQP4–/– mice i.c.v. injected with AAV9 vectors (normalized to vg in the brain). The vg copy per host genome (vg/cell) was determined by quantitative PCR of extracted genomic DNA and normalized to the number of copies of the mouse lamin β gene. (B) Two weeks after AAV9-CBh-ScGFP administration, mice were sacrificed and peripheral organs were harvested, post-fixed, and vibratome sectioned. Confocal micrographs showing GFP expression (green) in systemic organs, heart and liver, following brain injections of AAV9 vectors (mean ± SEM). Original magnification, ×20. P values were calculated by unpaired, 2-tailed Student’s t test. *P < 0.05. All experiments were conducted in quadruplicate, and representative images are shown.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts